Gabapentin Capsule
Product Images NDC 71335-1655

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1655). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Fig1)

This appears to be a formula for calculating a medical indicator known as "Lt" based on a patient's age and weight, as well as their creatinine level. However, it is not clear what "Lt" represents or what use this formula has in clinical practice.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

This appears to be a graph or chart related to a study on pain management. It displays the mean pain score on a vertical axis and has a grid with time periods labeled on the horizontal axis. The study seems to have had two periods - a titration period and a fixed dose period lasting 5 weeks each. The two treatments compared were a placebo and gabapentin at a dosage of 3600 mg/day. It is not possible to provide further information without additional context.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

This is a chart or table showing pain scores for different treatments over a course of 4 weeks. The treatments include a placebo, 1800 mg/day of gabapentin, and 2400 mg/day of gabapentin. The pain scores were measured at baseline and at the end of the 4-week fixed dose period. However, there is not enough context to understand the units or scale of the pain scores.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

The text describes a graph titled "Proportion of Responders" showing the percentage of patients in controlled PHN studies who had a reduction of at least 50% in their pain score. The graph shows the data for two studies, including the percentage of responders for those on a placebo or taking different dosages of GBP (an experimental drug). The text also includes some statistical notation and errors, but the information provided is still relatively clear.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

FDA Label Image

Chemical Structure (Gabapentin Str)

FDA Label Image

Label Image (Lbl713351655)

This is a package label for Neurontin 100mg Capsules manufactured by Aurobindo Pharma Limited. The label also includes information about the packaging company, Bryant Ranck Prepack, the expiration date, NDC number, and storage instructions. It is advised to keep the medication out of reach of children.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.